FindTrial
Sign In

Neurobiology of Opioid Dependence: 2 - 2

Neurobiology of Opioid Dependence: 2

Status
Withdrawn
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00000193
Enrollment
0
Registered
1999-09-21
Start date
1993-01-31
Completion date
1998-01-31
Last updated
2015-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid-Related Disorders

Keywords

Opioid disorders

Brief summary

The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.

Interventions

DRUGGamma hydroxybutyric

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Yale University
Lead SponsorOTHER

Study design

Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
MALE
Healthy volunteers
No

Inclusion criteria

Please contact site for information.

Design outcomes

Primary

MeasureTime frame
Behavioral, subjective, measures of naloxone-preci—
Phsyiological, neuroendocrine measures of naloxone—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026